Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1334953rdf:typepubmed:Citationlld:pubmed
pubmed-article:1334953lifeskim:mentionsumls-concept:C2239176lld:lifeskim
pubmed-article:1334953lifeskim:mentionsumls-concept:C1521827lld:lifeskim
pubmed-article:1334953lifeskim:mentionsumls-concept:C0304231lld:lifeskim
pubmed-article:1334953lifeskim:mentionsumls-concept:C0947677lld:lifeskim
pubmed-article:1334953pubmed:issue12lld:pubmed
pubmed-article:1334953pubmed:dateCreated1993-1-28lld:pubmed
pubmed-article:1334953pubmed:abstractTextAn isotopic exchange method was used to label lipiodol with 131I. The labelling efficiency was > 92.5%, and the radiochemical purity of [131I]lipiodol was above 98% as determined by ITLC. The influencing factors e.g. the heating temperature, reaction time, pH and storage conditions were studied and the optimum conditions were determined. In a pilot study injecting [131I]lipiodol for the treatment of hepatoma, about 70% of hepatoma patients had a response to the treatment with a reduction of alpha-fetoprotein and decrease of hepatoma sizes. The overall median survival was 9 months (range 2-17 months).lld:pubmed
pubmed-article:1334953pubmed:languageenglld:pubmed
pubmed-article:1334953pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1334953pubmed:citationSubsetIMlld:pubmed
pubmed-article:1334953pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1334953pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1334953pubmed:statusMEDLINElld:pubmed
pubmed-article:1334953pubmed:monthDeclld:pubmed
pubmed-article:1334953pubmed:issn0883-2889lld:pubmed
pubmed-article:1334953pubmed:authorpubmed-author:ChiC WCWlld:pubmed
pubmed-article:1334953pubmed:authorpubmed-author:WangA YAYlld:pubmed
pubmed-article:1334953pubmed:authorpubmed-author:LuiW YWYlld:pubmed
pubmed-article:1334953pubmed:authorpubmed-author:ChanW KWKlld:pubmed
pubmed-article:1334953pubmed:authorpubmed-author:LoJ GJGlld:pubmed
pubmed-article:1334953pubmed:authorpubmed-author:WeiY YYYlld:pubmed
pubmed-article:1334953pubmed:issnTypePrintlld:pubmed
pubmed-article:1334953pubmed:volume43lld:pubmed
pubmed-article:1334953pubmed:ownerNLMlld:pubmed
pubmed-article:1334953pubmed:authorsCompleteYlld:pubmed
pubmed-article:1334953pubmed:pagination1431-5lld:pubmed
pubmed-article:1334953pubmed:dateRevised2009-6-4lld:pubmed
pubmed-article:1334953pubmed:meshHeadingpubmed-meshheading:1334953-...lld:pubmed
pubmed-article:1334953pubmed:meshHeadingpubmed-meshheading:1334953-...lld:pubmed
pubmed-article:1334953pubmed:meshHeadingpubmed-meshheading:1334953-...lld:pubmed
pubmed-article:1334953pubmed:meshHeadingpubmed-meshheading:1334953-...lld:pubmed
pubmed-article:1334953pubmed:meshHeadingpubmed-meshheading:1334953-...lld:pubmed
pubmed-article:1334953pubmed:meshHeadingpubmed-meshheading:1334953-...lld:pubmed
pubmed-article:1334953pubmed:meshHeadingpubmed-meshheading:1334953-...lld:pubmed
pubmed-article:1334953pubmed:year1992lld:pubmed
pubmed-article:1334953pubmed:articleTitlePreparation of [131I]lipiodol as a hepatoma therapeutic agent.lld:pubmed
pubmed-article:1334953pubmed:affiliationInstitute of Nuclear Science, National Tsing Hua University, Hsinchu, Taiwan, Republic of China.lld:pubmed
pubmed-article:1334953pubmed:publicationTypeJournal Articlelld:pubmed